Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sciele Pharma has extended its alliance with Sanofi-aventis by entering into a new exclusive, three-year agreement to market Allegra Orally Disintegrating Tablets or ODT and Allegra Oral Suspension or OS in the pediatric market in the US.
Subscribe to our email newsletter
Under the terms of this agreement, Sciele will be responsible for all sales and marketing programs associated with these products in the US and will share revenues on both Allegra OS and ODT. Sciele expects to launch Allegra ODT in March 2008 through its 100 pediatric sales representatives.
Allegra OS, 30mg/5ml (6mg/ml), is indicated for the relief of symptoms such as sneezing, runny nose, itchy nose/palate/throat, and itchy watery, red eyes associated with seasonal allergic rhinitis in children two to 11 years of age. It is also indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (CIU) in children six months to 11 years. Allegra ODT, 30mg, treats the same seasonal allergy symptoms and CIU in children 6 to 11 years of age in a convenient formula that dissolves on the tongue and can be taken with or without water.
Patrick Fourteau, president and CEO of Sciele Pharma, said: “We continue to execute our strategy of forming partnerships with major pharmaceutical companies to capitalize on the full market potential of key branded products and maximize profits in cost-efficient manner.”